Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Declines By 59.2%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a large drop in short interest in October. As of October 15th, there was short interest totalling 9,700 shares, a drop of 59.2% from the September 30th total of 23,800 shares. Based on an average daily trading volume, of 149,800 shares, the short-interest ratio is currently 0.1 days. Currently, 0.9% of the shares of the stock are short sold.

ZyVersa Therapeutics Price Performance

NASDAQ ZVSA opened at $2.10 on Monday. The business’s 50 day moving average price is $2.48 and its 200-day moving average price is $3.83. ZyVersa Therapeutics has a fifty-two week low of $1.90 and a fifty-two week high of $42.70.

ZyVersa Therapeutics (NASDAQ:ZVSA) last released its quarterly earnings results on Friday, August 9th. The company reported ($3.31) EPS for the quarter, topping analysts’ consensus estimates of ($5.20) by $1.89. On average, equities research analysts expect that ZyVersa Therapeutics will post -22.7 earnings per share for the current year.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.